[177lu]lu-akir001
Poorly Differentiated Thyroid Gland Carcinoma
Explore 6 assets in Poorly Differentiated Thyroid Gland Carcinoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Karolinska University Hospital
Modality
radiopharmaceutical
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06639191CT.gov [177Lu]Lu-AKIR001 First-in-human Study | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Poorly Differentiated Thyroid Gland Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [177lu]lu-akir001 (this asset) | Karolinska University Hospital | Early P1 | C · 39 |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | CCC |
| Fludarabine | M.D. Anderson Cancer Center | P2 | CCC |
| Lifileucel | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Gefitinib | National Cancer Institute (NCI) | N/A | NR |
Other indications for [177lu]lu-akir001
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cervical Carcinoma | — | Early P1 | C · 39 |
| Vulvar Carcinoma | — | Early P1 | C · 39 |
| Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [177lu]lu-akir001 in Poorly Differentiated Thyroid Gland Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/177lulu-akir001-poorly-differentiated-thyroid-gland-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →